Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. (TARS) is a commercial-stage biopharmaceutical leader pioneering novel therapies for underserved ophthalmic conditions. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, clinical developments, and strategic initiatives driving innovation in eye care therapeutics.
Access authoritative updates on XDEMVY commercialization progress, pipeline advancements for TP-04 and TP-05, and financial performance metrics. Our curated collection includes earnings reports, FDA correspondence, peer-reviewed research publications, and partnership announcements – all essential for understanding TARS's market position.
Key updates cover:
• Prescription drug approval statuses
• Clinical trial phase completions
• Commercialization partnerships
• Quarterly financial disclosures
Bookmark this page for unfiltered access to Tarsus Pharmaceuticals' official communications. For comprehensive analysis of how these developments impact the biopharmaceutical landscape, consult your financial advisor and review SEC filings.
Tarsus Pharmaceuticals reported significant progress in its pipeline and financial results for Q3 2021. The company is on track to complete enrollment in the Saturn-2 Phase 3 trial for TP-03 by year-end, with topline data expected in Q1 2022. They presented new data highlighting a large unmet need in Demodex blepharitis. Financially, Tarsus posted a net loss of $15.7 million this quarter, up from $10.1 million a year prior, with increased R&D and administrative expenses totaling $10.2 million and $6.7 million respectively. Cash reserves are at $184 million, supporting operations into mid-2023.
Tarsus Pharmaceuticals (NASDAQ: TARS) presented data on Demodex blepharitis at the AAOpt 2021 Annual Meeting, revealing it accounts for 69% of blepharitis cases. The study found existing treatments like tea tree oil are ineffective, highlighting a need for better solutions. The Atlas study noted significant psychosocial burdens faced by 80% of patients, with many suffering for over four years without diagnosis. Tarsus's investigational drug, TP-03, is currently in Phase 3 trials and aims to address this unmet medical need.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that its President and CEO, Bobak Azamian, will present a corporate update at the Virtual Credit Suisse 30th Annual Healthcare Conference.
The presentation is scheduled for November 8th at 11:40 AM PT / 2:40 PM ET. Interested parties can view the webcast on the company's website, with a replay available within 48 hours. Tarsus focuses on innovative treatments in eye care, including its lead candidate TP-03, currently in a Phase 3 trial for Demodex blepharitis and Meibomian Gland Disease.
Tarsus Pharmaceuticals (NASDAQ: TARS) has appointed Rosemary A. Crane to its Board of Directors, where she will chair the newly formed Science and Technology Committee. With over 30 years in the pharmaceutical industry, Crane's expertise spans executive leadership and commercialization. Her role is deemed crucial as Tarsus advances its pipeline, particularly TP-03, aimed at treating Demodex blepharitis. Company executives express confidence in Crane's ability to drive innovation and enhance value during significant upcoming milestones.
Tarsus Pharmaceuticals (TARS) announced positive results from the Saturn-1 trial for TP-03, a treatment for Demodex blepharitis, achieving primary and secondary endpoints. 81% of patients had a clinically meaningful collarette cure. The company also initiated the Saturn-2 trial and the Phase 1 Callisto trial for Lyme disease prevention. Financially, Tarsus reported a net income of $6.3 million for Q2 2021, a significant increase from a net loss of $3.3 million in Q2 2020. Cash and equivalents were $177 million as of June 30, 2021.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced promising results from its Saturn-1 Phase 2b/3 trial for TP-03, targeting Demodex blepharitis. A significant 95% of patients achieved ≤0.5 mites per lash, and 93% improved by at least one collarette grade. Safety analysis showed no clinically significant adverse effects. Additionally, the Titan study revealed 58% of U.S. eye care patients have collarettes, indicating a high prevalence of the condition. Tarsus plans to submit a New Drug Application for TP-03 if upcoming Saturn-2 trial results are favorable.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that its CEO, Bobak Azamian, will present a corporate update at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14 at 1:30 PM ET. Tarsus, a late clinical-stage biopharmaceutical company, focuses on unmet medical needs, particularly in eye care. The company is advancing its pipeline, which includes TP-03 for Demodex blepharitis and Meibomian Gland Disease, and TP-05 for Lyme disease prevention. A live webcast of the presentation will be accessible, along with a replay for 90 days.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that CEO Bobak Azamian will participate in a fireside chat at the Raymond James 2021 Human Health Innovation Conference on June 22 at 12 PM ET. The chat will provide a corporate update on Tarsus's focus on unmet medical needs in eye care and other therapeutic areas. Tarsus is currently conducting clinical trials for its lead product TP-03, targeting Demodex blepharitis and Meibomian Gland Disease, and TP-05, aimed at preventing Lyme disease. The webcast will be available for replay on their official site for 90 days.
Tarsus Pharmaceuticals announced the success of its pivotal Phase 2b/3 Saturn-1 trial for TP-03, demonstrating significant outcomes in treating Demodex blepharitis. The trial met all primary and secondary endpoints, with 81% of patients achieving clinically meaningful collarette cures by day 43. Notably, TP-03 showed a good safety profile, with no serious treatment-related adverse events. This is crucial as Demodex blepharitis affects an estimated 25 million Americans and currently lacks FDA-approved therapies. A conference call to discuss detailed results is scheduled for today at 8:00 a.m. ET.
Tarsus Pharmaceuticals (NASDAQ: TARS) has announced a webcast and conference call scheduled for June 21, 2021, at 8:00 a.m. ET, to discuss results from the Saturn-1 Phase 2b/3 trial of TP-03 for treating Demodex blepharitis. The event will provide insights into the trial outcomes and a corporate update. TP-03 is a key candidate in Tarsus' pipeline, aimed at addressing high unmet needs in eye care. The company is also developing TP-05 for Lyme disease. Full details will be available on Tarsus' website post-event.
FAQ
What is the current stock price of Tarsus Pharmaceuticals (TARS)?
What is the market cap of Tarsus Pharmaceuticals (TARS)?
